Future Directions: Evolving Role of Nonfactor Replacement Therapies

Learn about the latest data on nonfactor replacement therapies and their evolving role in the management of hemophilia A in by downloading this slideset.
Miguel A. Escobar, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.94 MB
Released: December 4, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Genentech, a member of the Roche Group
Sanofi Genzyme Corporation
Takeda Pharmaceutical Company Ltd

Related Content

On-demand Webcast updated with data from ASH 2020 with expert faculty discussing recent data on management of hemophilia A, presented by Clinical Care Options (CCO)

Miguel A. Escobar, MD
Program Director
Michael Callaghan, MD person default Rebecca Kruse-Jarres, MD, MPH
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: February 25, 2021 Expired: February 24, 2022

Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD: top picks of nonmalignant hematology studies from ASH 2020 as reported by CCO

Hanny Al-Samkari, MD Mark A. Schroeder, MD Sujit Sheth, MD Released: February 24, 2021

From Clinical Care Options (CCO), expert answers to audience questions from 2 live meetings on contemporary management of hemophilia A

Michael Callaghan, MD Miguel A. Escobar, MD person default Rebecca Kruse-Jarres, MD, MPH Released: February 16, 2021

Review expert perspectives and insights on the most clinically relevant data on ITP, hemophilia, β-thalassemia, sickle cell disease, and GVHD presented at the Hematology 2020 annual meeting.

Hanny Al-Samkari, MD Mark A. Schroeder, MD Sujit Sheth, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: February 11, 2021 Expired: February 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue